HE3286 ( DrugBank: HE3286 )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1
97	潰瘍性大腸炎	1

46. 悪性関節リウマチ

---

臨床試験数 : 4,325 /  薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00712114 (ClinicalTrials.gov)	July 2008	6/7/2008	Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis	A Phase I/II, Open Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Anti-Inflammatory Activity of HE3286 When Administered Orally for 29 Days to Patients With Rheumatoid Arthritis on a Stable Dose of Methotrexate	Rheumatoid Arthritis	Drug: HE3286	Harbor Therapeutics	NULL	Completed	18 Years	75 Years	Both	14	Phase 1/Phase 2	United States

97. 潰瘍性大腸炎

---

臨床試験数 : 2,527 /  薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00628433 (ClinicalTrials.gov)	February 2008	25/2/2008	Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis	A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis	Ulcerative Colitis	Drug: Placebo;Drug: HE3286	Harbor Therapeutics	NULL	Completed	18 Years	65 Years	Both	27	Phase 1/Phase 2	United States